fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Hyoscine butylbromide

All products: Limited Use (codes 481)

Accel-Hyoscine · DIN 02512335 · 10 mg · tablet

Limited Use, Reason for Use code 481 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 481 required
Write on scriptReason for Use code 481 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 481
Reason for Use code 481 For the management of patients receiving palliative care*. Coverage limit: LU Authorization Period: 1 year Coverage limit: *The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
1 brand, same coverage
Accel-Hyoscine · DIN 02512335 Manufacturer: Accel Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2021-08-19 · brand ACCEL-HYOSCINE · ATC A03BB01 BUTYLSCOPOLAMINE · form Tablet · route Oral · ingredients HYOSCINE BUTYLBROMIDE 10 MG · company Accel pharma inc · schedule Ethical
Re-check Health Canada status and shortages (live) · Health Canada product record

Accel-Hyoscine: Formulary list price $0.27 per unit (the source does not state the unit; exact figure $0.2711). What the ministry pays, not the patient.

Ministry pays: $0.2711 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02512335)

Source record
DIN 02512335: Accel-Hyoscine Raw flags: sec12=Y, sec3=Y Item: 120800009; group id 204; item number 0373; lccId 00336; manufacturer id ACC Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.2711; ministry $0.2711 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02512335 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100163
Interchangeable products
Buscopan · DIN 00363812 · $0.2711
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02512335
Shortage record checked October 6, 2026
Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ACLIDINIUM BROMIDE, BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

ACLIDINIUM BROMIDE

· 1 products · General benefit · strengths: 400mcg/actuation · Pd Inh-60 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 12:08 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE BUSCOPAN (hyoscine butylbromide) tablets are indicated for:  The relief of smooth muscle spasm/cramping of the gastrointestinal system and its associated pain and discomfort. BUSCOPAN solution is indicated for:  The relief of acute genitourinary or gastrointestinal spasm (e.g., renal or biliary colic), or to produce smooth muscle relaxation prior to radiological procedures such as pyelography or other diagnostic procedures where spasm may be a problem (e.g., gastro- duodenal endoscopy). Geriatrics: No data is available. Buscopan® Prescribing Information Page 3 of 28 Pediatrics: No data is available. https://pdf.hres.ca/dpd_pm/00060599.PDF PM date: March 31, 2021 Source product: BUSCOPAN; DIN 00363812; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.